Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor proline- and glutamine-rich (SFPQ) is a multifunctional nuclear RNA- and DNA-binding protein involved in alternative splicing, transcriptional regulation, RNA transport, DNA repair, and apoptosis. SFPQ is a member of the DBHS protein family and forms complexes with partners such as NONO/p54^nrb^ and PSPC1. It regulates vital cellular processes, including the control of pro- and antiapoptotic isoforms of caspases through modulation of alternative splicing factors (notably SRSF2). SFPQ is essential for cell viability; its upregulation is linked to platinum-chemoresistance in ovarian cancer and viral mRNA processing, and it interacts with several proteins including PTBP1 and NONO. Inhibition or knockdown of SFPQ leads to apoptosis and enhanced sensitivity to DNA-damaging agents.
Drugs (cisplatin, carboplatin): induce DNA damage and apoptosis; SFPQ overexpression mediates resistance by promoting antiapoptotic transcripts via splicing regulation. Caspase inhibitors: block caspase activation downstream of SFPQ knockdown, rescuing cell viability.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor proline- and glutamine-rich (SFPQ).